Question · asked by 1 review
Anticonvulsants (gabapentin + alpha lipoic acid) vs placebo: Relief of burning/discomfort (symptom relief; pain intensity)
- Population
- People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
- Intervention
- Anticonvulsants (gabapentin + alpha lipoic acid)
- Comparison
- placebo
- Outcome
- Relief of burning/discomfort (symptom relief; pain intensity)
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Anticonvulsants (gabapentin 300 mg/day + alpha lipoic acid 600 mg/day) vs Placebo Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such… · short-term (up to 3 months), gabapentin with adjunctive ALA Interventions for treating burning mouth syndrome (2016) · Cochrane All outcomes | SoF2 subgroup. Gabapentin + adjunctive ALA vs placebo forms one of two subgroups of the anticonvulsant symptom-relief estimate (RR 4.00, 2.09 to 7.67); no between-subgroup difference vs gabapentin alone; 100… | 1 study · 40 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomes | 2015-12 | Not listed | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.